AMGN compared with PTHS: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

PTHSPelthos Therapeutics Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

PTHSPelthos Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

Q3 FY25±3.7%▲+7.81%×2.11

PTHS

Reportimpliedrealized× implied

Q2 FY26—▲+0.14%—

May 14 '26—▲+6.46%—

Q1 FY26

= impliedAMGN realized, solidPTHS realized, hatchedOne scale, both sides: full bar = 9%× = |realized| ÷ impliedSource: market data

—

▼−4.62%

—

Nov 13 '25—▼−7.27%—

AMGNAmgen Inc

465.45· pre 466.36· delayed

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

PTHSPelthos Therapeutics Inc.

11.38· pre 11.40· delayed

Pre-marketNov 2 '26delayed

Mkt cap$36.0MRevenue$16MQ2 FY26Revenue—

Compare

Pre-marketNov 2 '26delayed

AMGNAmgen Inc

PTHSPelthos Therapeutics Inc.

465.45pre 466.36delayed

Price

11.38pre 11.40delayed

$251.6B

Mkt cap

$36.0M

Q2 FY26$10.1B

Revenue

$16MQ2 FY26

FY25$36.8B

Revenue

—

AMGN465.45vsPTHS11.38Pre-marketNov 2 '26delayed